Do analysts rate VMD or PIII?

P3 Health Partners has a consensus target price of $17.00, suggesting a potential upside of 64.89%. Given P3 Health Partners' higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Viemed Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viemed Healthcare 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer PIII or TACO?

P3 Health Partners currently has a consensus price target of $17.00, suggesting a potential upside of 64.89%. Given P3 Health Partners' stronger consensus rating and higher probable upside, research analysts plainly believe P3 Health Partners is more favorable than Berto Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PIII or TACO?

Berto Acquisition has lower revenue, but higher earnings than P3 Health Partners. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio P3 Health Partners $1.46B 0.05 -$147.95M -$33.00 N/A Berto Acquisition N/A N/A N/A N/A N/A

Is PIII or TACO more profitable?

Berto Acquisition has a net margin of 0.00% compared to P3 Health Partners' net margin of -6.55%. Company Net Margins Return on Equity Return on Assets P3 Health Partners -6.55% N/A -16.40% Berto Acquisition N/A N/A N/A

P3 Health Partners (PIII) Competitors

$10.31 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

PIII vs. VMD, TACO, SBC, BDSX, and INFU

Should you buy P3 Health Partners stock or one of its competitors? P3 Health Partners's main competitors and comparable companies include Viemed Healthcare (VMD), Berto Acquisition (TACO), SBC Medical Group (SBC), Biodesix (BDSX), and InfuSystem (INFU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does P3 Health Partners compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Viemed Healthcare has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

P3 Health Partners has a consensus target price of $17.00, suggesting a potential upside of 64.89%. Given P3 Health Partners' higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Viemed Healthcare has a net margin of 4.81% compared to P3 Health Partners' net margin of -6.55%. Viemed Healthcare's return on equity of 10.16% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	4.81%	10.16%	7.22%
P3 Health Partners	-6.55%	N/A	-16.40%

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by company insiders. Comparatively, 10.9% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Viemed Healthcare had 5 more articles in the media than P3 Health Partners. MarketBeat recorded 5 mentions for Viemed Healthcare and 0 mentions for P3 Health Partners. Viemed Healthcare's average media sentiment score of 1.79 beat P3 Health Partners' score of 0.00 indicating that Viemed Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Viemed Healthcare	Very Positive
P3 Health Partners	Neutral

Viemed Healthcare has higher earnings, but lower revenue than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$270.28M	1.25	$14.93M	$0.36	24.58
P3 Health Partners	$1.46B	0.05	-$147.95M	-$33.00	N/A

Summary

Viemed Healthcare beats P3 Health Partners on 11 of the 15 factors compared between the two stocks.

How does P3 Health Partners compare to Berto Acquisition?

P3 Health Partners (NASDAQ:PIII) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

P3 Health Partners has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

Berto Acquisition has a net margin of 0.00% compared to P3 Health Partners' net margin of -6.55%.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
Berto Acquisition	N/A	N/A	N/A

In the previous week, Berto Acquisition had 3 more articles in the media than P3 Health Partners. MarketBeat recorded 3 mentions for Berto Acquisition and 0 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.00 equaled Berto Acquisition'saverage media sentiment score.

Company	Overall Sentiment
P3 Health Partners	Neutral
Berto Acquisition	Neutral

7.8% of P3 Health Partners shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Berto Acquisition has lower revenue, but higher earnings than P3 Health Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.05	-$147.95M	-$33.00	N/A
Berto Acquisition	N/A	N/A	N/A	N/A	N/A

P3 Health Partners currently has a consensus price target of $17.00, suggesting a potential upside of 64.89%. Given P3 Health Partners' stronger consensus rating and higher probable upside, research analysts plainly believe P3 Health Partners is more favorable than Berto Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

P3 Health Partners beats Berto Acquisition on 7 of the 10 factors compared between the two stocks.

How does P3 Health Partners compare to SBC Medical Group?

P3 Health Partners (NASDAQ:PIII) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

P3 Health Partners presently has a consensus target price of $17.00, suggesting a potential upside of 64.89%. SBC Medical Group has a consensus target price of $8.50, suggesting a potential upside of 112.50%. Given SBC Medical Group's stronger consensus rating and higher possible upside, analysts clearly believe SBC Medical Group is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

P3 Health Partners has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

SBC Medical Group has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.05	-$147.95M	-$33.00	N/A
SBC Medical Group	$173.61M	2.37	$50.99M	$0.47	8.51

SBC Medical Group has a net margin of 27.99% compared to P3 Health Partners' net margin of -6.55%. SBC Medical Group's return on equity of 18.47% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
SBC Medical Group	27.99%	18.47%	13.10%

In the previous week, SBC Medical Group had 21 more articles in the media than P3 Health Partners. MarketBeat recorded 21 mentions for SBC Medical Group and 0 mentions for P3 Health Partners. SBC Medical Group's average media sentiment score of 0.51 beat P3 Health Partners' score of 0.00 indicating that SBC Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Neutral
SBC Medical Group	Positive

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

SBC Medical Group beats P3 Health Partners on 14 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Biodesix?

P3 Health Partners (NASDAQ:PIII) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

P3 Health Partners has a net margin of -6.55% compared to Biodesix's net margin of -26.97%. P3 Health Partners' return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
Biodesix	-26.97%	-788.19%	-30.33%

In the previous week, Biodesix had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for Biodesix and 0 mentions for P3 Health Partners. Biodesix's average media sentiment score of 1.31 beat P3 Health Partners' score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Neutral
Biodesix	Positive

P3 Health Partners has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

P3 Health Partners currently has a consensus price target of $17.00, suggesting a potential upside of 64.89%. Biodesix has a consensus price target of $31.33, suggesting a potential upside of 17.66%. Given P3 Health Partners' higher possible upside, equities analysts clearly believe P3 Health Partners is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biodesix has lower revenue, but higher earnings than P3 Health Partners. Biodesix is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.05	-$147.95M	-$33.00	N/A
Biodesix	$88.50M	3.17	-$35.26M	-$3.17	N/A

Summary

Biodesix beats P3 Health Partners on 10 of the 17 factors compared between the two stocks.

How does P3 Health Partners compare to InfuSystem?

P3 Health Partners (NASDAQ:PIII) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

InfuSystem has a net margin of 1.12% compared to P3 Health Partners' net margin of -6.55%. InfuSystem's return on equity of 2.78% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
InfuSystem	1.12%	2.78%	1.41%

In the previous week, InfuSystem had 3 more articles in the media than P3 Health Partners. MarketBeat recorded 3 mentions for InfuSystem and 0 mentions for P3 Health Partners. InfuSystem's average media sentiment score of 1.73 beat P3 Health Partners' score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Neutral
InfuSystem	Very Positive

P3 Health Partners has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

P3 Health Partners currently has a consensus price target of $17.00, suggesting a potential upside of 64.89%. InfuSystem has a consensus price target of $16.67, suggesting a potential upside of 36.50%. Given P3 Health Partners' higher probable upside, equities analysts plainly believe P3 Health Partners is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

InfuSystem has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.05	-$147.95M	-$33.00	N/A
InfuSystem	$143.34M	1.72	$870K	$0.41	29.78

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

InfuSystem beats P3 Health Partners on 12 of the 16 factors compared between the two stocks.

Get P3 Health Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PIII vs. The Competition

Export

Metric	P3 Health Partners	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$74.85M	$9.84B	$7.33B	$12.82B
Dividend Yield	N/A	2.55%	2.54%	10.78%
P/E Ratio	-0.31	34.38	272.90	24.25
Price / Sales	0.05	4.95	624.39	94.51
Price / Cash	N/A	24.64	29.03	36.90
Price / Book	-0.48	5.40	11.25	6.42
Net Income	-$147.95M	$309.96M	$3.47B	$348.89M
7 Day Performance	-2.46%	0.99%	2.33%	0.57%
1 Month Performance	7.17%	2.30%	7.72%	4.90%
1 Year Performance	43.39%	15.69%	25.22%	17.06%

P3 Health Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PIII P3 Health Partners	2.4584 of 5 stars	$10.31 flat	$17.00 +64.9%	+43.4%	$74.85M	$1.46B	N/A	500
VMD Viemed Healthcare	3.6765 of 5 stars	$9.28 -0.4%	N/A	+21.1%	$354.98M	$270.28M	25.78	1,382	News Coverage Positive News
TACO Berto Acquisition	N/A	$10.47 +0.2%	N/A	+1.4%	$341.09M	N/A	N/A	7,892	Analyst Downgrade
SBC SBC Medical Group	4.0746 of 5 stars	$3.20 +3.9%	$8.50 +165.6%	-6.8%	$315.94M	$173.61M	8.21	N/A	Analyst Revision
BDSX Biodesix	4.2104 of 5 stars	$24.31 -2.2%	$31.33 +28.9%	+193.7%	$262.30M	$88.50M	N/A	220	Positive News Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PIII) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

P3 Health Partners (PIII) Competitors

PIII vs. VMD, TACO, SBC, BDSX, and INFU

How does P3 Health Partners compare to Viemed Healthcare?

Summary

How does P3 Health Partners compare to Berto Acquisition?

Summary

How does P3 Health Partners compare to SBC Medical Group?

Summary

How does P3 Health Partners compare to Biodesix?

Summary

How does P3 Health Partners compare to InfuSystem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

P3 Health Partners (PIII) Competitors

PIII vs. VMD, TACO, SBC, BDSX, and INFU

How does P3 Health Partners compare to Viemed Healthcare?

Which has more volatility and risk, VMD or PIII?

Do analysts rate VMD or PIII?

Is VMD or PIII more profitable?

Do institutionals & insiders have more ownership in VMD or PIII?

Does the media prefer VMD or PIII?

Which has better valuation and earnings, VMD or PIII?

Summary

How does P3 Health Partners compare to Berto Acquisition?

Which has more risk and volatility, PIII or TACO?

Is PIII or TACO more profitable?

Does the media favor PIII or TACO?

Do institutionals and insiders hold more shares of PIII or TACO?

Which has preferable earnings and valuation, PIII or TACO?

Do analysts prefer PIII or TACO?

Summary

How does P3 Health Partners compare to SBC Medical Group?

Do analysts prefer PIII or SBC?

Which has more risk & volatility, PIII or SBC?

Which has stronger valuation and earnings, PIII or SBC?

Is PIII or SBC more profitable?

Does the media favor PIII or SBC?

Do insiders and institutionals hold more shares of PIII or SBC?

Summary

How does P3 Health Partners compare to Biodesix?

Is PIII or BDSX more profitable?

Does the media favor PIII or BDSX?

Which has more volatility & risk, PIII or BDSX?

Do analysts prefer PIII or BDSX?

Do insiders & institutionals hold more shares of PIII or BDSX?

Which has better valuation & earnings, PIII or BDSX?

Summary

How does P3 Health Partners compare to InfuSystem?

Is PIII or INFU more profitable?

Does the media favor PIII or INFU?

Which has more volatility & risk, PIII or INFU?

Do analysts recommend PIII or INFU?

Which has better valuation and earnings, PIII or INFU?

Do insiders and institutionals hold more shares of PIII or INFU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools